11 March 2002
Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis.
Urszula Trafikowska, Anna Trafikowska, Andrzej Adamowicz, Bronisław Zachara, Jacek ManitiusMed Sci Monit 2002; 8(3): CR202-205 :: ID: 420901
Abstract
BACKGROUND: The kidney accumulates the highest level of selenium (Se) inthe organism and is the major source of plasma glutathione peroxidase (GSH-Px). Se, as an integral partof the active site of GSH-Px, plays an important role in protecting cell membranes from oxidative damage.Decreased blood Se levels and GSH-Px activity are common in chronic renal failure (CRF) patients. Ourstudy was an effort to evaluate the effect of erythropoietin (EPO) therapy and Se supplementation forCRF patients undergoing regular hemodialysis (HD) on blood Se, red cell glutathione (GSH), and bloodlipid peroxidation product levels, and on blood activity levels of GSH-Px and blood superoxide dismutase(SOD). MATERIAL/METHODS: Our subjects were divided into three groups: I - CRF patients on regular HDand EPO, II - HD patients receiving EPO and Se, and III - healthy controls. Se levels, SOD and GSH-Pxactivities were measured spectrofluorometrically, the GSH level by Beutler's colorimetric method, andlipid peroxidation products using TBARS. RESULTS: EPO therapy with Se supplementation significantly increasedwhole blood and plasma Se in HD patients, and raised red cell GSH-Px activity, but plasma GSH-Px activity,plasma superoxide dismutase, and plasma and red cell TBARS did not respond to Se supplementation. EPOalone showed no effect on these parameters. CONCLUSIONS: Treatment with EPO and supplementation withSe significantly increased the element concentration in whole blood and plasma, and GSH-Px activity inred cells. Plasma GSH-Px activity did not respond to Se.
Keywords: Adolescent, Dietary Supplements, Erythropoietin, Kidney Failure, Chronic, Renal Dialysis, Research Support, Non-U.S. Gov, Selenium, Spectrometry, Fluorescence, Time Factors, Uremia
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952